Anebulo Pharmaceuticals, Inc. financial data

Symbol
ANEB on Nasdaq
Location
C/O Anebulo Pharmaceuticals, Inc., 1017 Ranch Road 620 South, Suite 107, Lakeway, TX
Fiscal year end
June 30
Latest financial report
Sep 29, 2025

Key Ratios

Label TTM Value / Value Unit Change %
Debt-to-equity 5.91 % -53.5%
Return On Equity -80.8 % +41.8%
Return On Assets -76.3 % +38.1%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 41.1M shares +58.4%
Common Stock, Shares, Outstanding 41.1M shares +58.4%
Entity Public Float 15.1M USD +59%
Common Stock, Value, Issued 41.1K USD +58.4%
Weighted Average Number of Shares Outstanding, Basic 33.8M shares +31%
Weighted Average Number of Shares Outstanding, Diluted 33.8M shares +31%

Income Statement

Label TTM Value / Value Unit Change %
Research and Development Expense 4.3M USD +21.2%
General and Administrative Expense 4.92M USD +3.44%
Operating Income (Loss) -9.22M USD -11%
Nonoperating Income (Expense) 739K USD +590%
Net Income (Loss) Attributable to Parent -8.48M USD -3.45%
Earnings Per Share, Basic 0 USD/shares +21.9%
Earnings Per Share, Diluted 0 USD/shares +21.9%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 11.6M USD +276%
Assets, Current 12M USD +241%
Other Assets, Noncurrent 183K USD -67.6%
Assets 12.1M USD +198%
Accounts Payable, Current 224K USD +43.3%
Accrued Liabilities, Current 264K USD +153%
Liabilities 488K USD +87.2%
Retained Earnings (Accumulated Deficit) -73.9M USD -13%
Stockholders' Equity Attributable to Parent 11.7M USD +206%
Liabilities and Equity 12.1M USD +198%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities -1.69M USD +38%
Common Stock, Shares Authorized 75M shares +50%
Common Stock, Shares, Issued 41.1M shares +58.4%
Common Stock, Par or Stated Value Per Share 0 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect -1.69M USD +38%
Deferred Tax Assets, Valuation Allowance 7.98M USD +24.5%
Deferred Tax Assets, Gross 7.98M USD +24.5%
Deferred Tax Assets, Operating Loss Carryforwards 5.15M USD +37.7%
Preferred Stock, Shares Issued 0 shares
Preferred Stock, Shares Authorized 2M shares 0%
Additional Paid in Capital 85.5M USD +23.6%
Preferred Stock, Shares Outstanding 0 shares
Interest Expense 100K USD +67.5%
Preferred Stock, Par or Stated Value Per Share 0 USD/shares 0%